Mylan loses bid to have US Teva patent infringement suit on Copaxone tossed out
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries is anxiously awaiting the start of a patent infringement trial against Mylan and Momenta/Sandoz in a US district court in New York City beginning 7 September. Both are looking to bring to market a generic version of Teva's multiple sclerosis drug Copaxone (glatiramer acetate) before Teva's key US patents protecting the drug expire in May 2014. Both were sued.